Back
Agios Pharmaceuticals 10K Form
Sell
28
AGIO
Agios Pharmaceuticals
Last Price:
$31.76
Seasonality Move:
9.03%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-02 | 10Q | AGIO/Agios Pharmaceuticals Quarterly |
| 2023-11-02 | 10Q | AGIO/Agios Pharmaceuticals Quarterly |
| 2023-08-03 | 10Q | AGIO/Agios Pharmaceuticals Quarterly |
| 2023-05-04 | 10Q | AGIO/Agios Pharmaceuticals Quarterly |
| 2022-11-03 | 10Q | AGIO/Agios Pharmaceuticals Quarterly |
| 2022-08-04 | 10Q | AGIO/Agios Pharmaceuticals Quarterly |
Receive AGIO News And Ratings
See the #1 stock for the next 7 days that we like better than AGIO
AGIO Financial Statistics
Sales & Book Value
| Annual Sales: | $36.5M |
|---|---|
| Cash Flow: | $-134.1M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $26.96 |
| Price / Book: | 1.19 |
Profitability
| EPS (TTM): | 11.34000 |
|---|---|
| Net Income (TTM): | $673.7M |
| Gross Margin: | $32.3M |
| Return on Equity: | 62.58% |
| Return on Assets: | 56.01% |
Agios Pharmaceuticals Earnings Forecast
Key Agios Pharmaceuticals Financial Ratios
-
The Gross Profit Margin over the past 12 years for AGIO is 88.59%.
-
The Selling, General & Administrative Expenses for AGIO have been equal to 429.57% of Gross Profit Margin.
-
The Research & Development expenses have been 825.49% of Revenue.
-
Per Share Earnings over the last 14 years have been positive in 5 years.
Agios Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | AGIO |
| CUSIP: | 00847X |
| Website: | agios.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 11.9 |
| Quick Ratio: | 11.06 |
Price-to-Earnings
| Trailing P/E Ratio: | 2.75 |
|---|---|
| Forward P/E Ratio: | 2.01 |
AGIO Technical Analysis vs Fundamental Analysis
Sell
28
Agios Pharmaceuticals (AGIO)
is a Sell
Is Agios Pharmaceuticals a Buy or a Sell?
-
Agios Pharmaceuticals stock is rated a SellThe current Agios Pharmaceuticals [AGIO] share price is $31.99. The Score for AGIO is 28, which is 44% below its historic median score of 50, and infers higher risk than normal.